Regulatory News:
Mauna Kea Technologies (Paris:MKEA) (NYSE Euronext: MKEA, FR0010609263), leader in optical biopsy market and the maker of Cellvizio, the fastest way to see cancer, today announced that the French President, François Hollande and Ms Anne Lauvergeon, President of the "Innovation 2030" Commission visited the company's headquarters this morning.
Sacha Loiseau, Founder and CEO of Mauna Kea Technologies, welcomed President Hollande and showed him around the offices in which ground-breaking technology opening a new era of medical imaging is developed. He was presented Cellvizio, the world's smallest microscope and a state-of-the art French invention. This unique technology helps physicians and surgeons in their diagnosis of several cancers by providing cellular level views of patients' internal tissues in real-time, enabling them to identify possible abnormalities, save valuable time and help orient patient management.
Founded in 2000, Mauna Kea Technologies was floated in 2011 on the NYSE Euronext Paris (MKEA). It's a fast-growing French "medtech" start-up that employs 110 people today, 75 of which are in Paris. It manufactures and exports Cellvizio internationally to many countries including the United States.
As co-lead of the Medical Devices and New Healthcare Equipments plan, one of the "34 industrial development plans to revive industry in France" launched this fall, Sacha Loiseau was able to discuss with the President and Ms Anne Lauvergeon. He was pleased at the attention received from President Hollande and at the government measures to help innovative French small and medium sized businesses.
He urged the President to streamline and accelerate the reimbursement process for new medical procedures by the French healthcare authorities in order for the patients to benefit from technological innovations such as Cellvizio in a much faster way. He also called for him to promote hi-tech small and medium-sized businesses access to public procurement contracts, reminding him that this is critical for them to grow and export from the French territory.
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company dedicated to the advent of optical biopsy. The company researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multicenter clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI tract, biliary and pancreatic ducts and lungs and during fine needle aspiration procedures.
For more information on Mauna Kea Technologies, visit www.maunakeatech.com
Contacts:
Mauna Kea Technologies
Eric Cohen
Vice-President Finance
Tel: +33 (0)1 70 08 09 70
investor-vpf@maunakeatech.com
or
France and Europe:
Gilles Dauxerre Madis Phileo
Tel: +33 (0)6 88 21 59 05
gilles.dauxerre@madisphileo.com
or
NewCap
Investor Relations
Florent Alba Pierre Laurent
Tel: +33 (0)1 44 71 94 94
maunakea@newcap.fr
